Verovaccines Announces EU-Wide Market Authorization for VeroBlue-3 and Strategic Out-Licensing Agreement

Verovaccines GmbH today announced that the European Commission has granted EU-wide market authorization for its VeroBlue-3 bluetongue vaccine, following the positive EMA opinion issued on March 12, 2026. The decision, granted under exceptional circumstances, marks the most significant milestone in the company’s history.

VeroBlue-3 is the first product developed on Verovaccines’ proprietary platform to receive regulatory approval, establishing the company as a fully integrated vaccine developer and marketing authorization holder (MAH) compliant with EMA standards. The authorization represents a major de-risking event, validating the platform’s regulatory pathway, GMP scalability, and suitability as a novel vaccine development engine.

In parallel, Verovaccines has entered into its first out-licensing agreement with an undisclosed top-10 global animal health company, covering manufacturing and EU-wide commercialization. The partnership enables rapid market access while confirming strong industry demand for the platform.

VeroBlue-3 leverages Verovaccines’ technology enabling rapid, cost-efficient vaccine development, low cost of goods, thermostability, and flexible combination with existing vaccines – key advantages for addressing fast-mutating pathogens such as bluetongue virus.

Building on its recent momentum, Verovaccines is engaging at the corporate level with several leading pharmaceutical organizations to evaluate broader applications of its validated platform technology across an expanded set of vaccine opportunities. These engagements encompass potential extensions into combination products and programs addressing rapidly evolving pathogens. Through selective external alignment, Verovaccines is positioned to unlock additional value from its platform while offering industry counterparts access to a rapid, scalable, and regulatory-proven pathway for vaccine development and commercialization.

Dr. Hanjo Hennemann, Managing Director and Co-founder of Verovaccines, said: “The EU authorization of VeroBlue-3 and our first out-licensing agreement validate both our technology and business model. We are now well positioned to scale, expand our pipeline, and unlock the full value of our platform.”

Dr. Ulrike Diesterbeck, DVM, Managing Director of Verovaccines, added: “This approval affirms the robustness and scalability of our platform and reinforces its capacity to support accelerated product development across a growing range of vaccine opportunities.”

About Verovaccines
Verovaccines GmbH is a Germany-based biotechnology company developing next-generation vaccines or animal health. Its proprietary platform enables rapid, cost-efficient development of scalable vaccines targeting a broad range of pathogens (and in particular highly variable types), with advantages including low cost of goods, thermostability, and combination flexibility.

Following its first EU market authorization and validation of GMP manufacturing through a strategic partner, Verovaccines is positioning itself as a high-impact vaccine platform company with strong partnering potential and a scalable development model.

For investor and media inquiries:

Verovaccines GmbH
Bluecherstrasse 26, 06120 Halle (Saale), Germany
Email: info@verovaccines.com
Website: https://verovaccines.com/